Key takeaways
- Dividend income crosses the border: US dividend stocks give Canadian investors access to sectors and business models that simply don’t exist on the TSX, from specialty insurance to semiconductor manufacturing to biotech, and many of these companies are growing their payouts at a pace most Canadian dividend payers can’t match.
- Growth and income aren’t exclusive: The standout names on this list aren’t just paying dividends for the sake of it. They’re backed by real earnings momentum in areas like cloud networking, gold mining, and electric vehicle infrastructure, meaning you’re not sacrificing capital appreciation potential just to collect a quarterly cheque.
- Watch withholding taxes and volatility: Canadians buying US dividend stocks face a 15% withholding tax in registered accounts like TFSAs (RRSPs get a treaty exemption), which eats into your yield. On top of that, some of these sectors, particularly gold miners and smaller industrial names, can swing hard on commodity prices or shifting government policy, so position sizing matters more than usual.
Most Canadian investors default to the TSX for dividend income. Makes sense. The tax treatment on eligible dividends is generous, and there’s no shortage of banks, pipelines, and telecoms paying you to hold them. But if that’s all you own, you’re fishing in a pretty small pond. The U.S. market gives you access to industries that barely exist on the TSX, and some of those companies are paying growing dividends backed by business models you simply can’t replicate with Canadian dividend stocks alone.
The catch, of course, is withholding tax. The IRS clips 15% off U.S. dividends paid to Canadians, which means you want to hold these in an RRSP where that withholding is waived under the tax treaty. Stick them in a TFSA and you’re giving up a chunk of your yield for no reason. That one decision, which account to use, can meaningfully change your after-tax return over a decade. If you’re looking for ideas on what to hold in your RRSP, U.S. dividend payers are a natural fit.
I wanted this list to be different from the usual suspects. You won’t find mega-cap tech names paying token 0.5% yields here. Instead, I focused on companies where the dividend is meaningful, the payout is sustainable, and there’s a real growth story underneath. Some of these are in sectors like insurance, semiconductors, and specialty manufacturing that Canadian investors rarely get exposure to through the TSX.
Diversification across borders isn’t just a nice idea. It’s a structural advantage. Canada’s market is heavily concentrated in financials, energy, and materials. Owning U.S. technology stocks or healthcare names gives your portfolio earnings streams tied to completely different economic drivers. When Canadian banks stumble or oil prices slide, those U.S. holdings can act as ballast.
The ten names below span insurance, tech, energy services, pharma, agriculture, gold, and more. Each one pays a dividend today with room to grow it, and each one brings something to the table that’s hard to find on the TSX.
In This Article
- Bristol-Myers Squibb Company (BMY)
- AT&T Inc. (T)
- Progressive Corporation (PGR)
- Altria Group Inc. (MO)
- Comcast Corporation (CMCSA)
- Verizon Communications Inc (VZ)
- Amgen Inc. (AMGN)
- Procter & Gamble Company (The) (PG)
- International Business Machines Corporation (IBM)
- PepsiCo Inc. (PEP)
Bristol-Myers Squibb Company (NYSE: BMY)
$58.31
Overall Grade7.0 / 10
Bristol-Myers Squibb Company, established in its current form in 1989 following a merger, is a global biopharmaceutical firm operating within the healthcare sector. It focuses on developing and commercializing innovative medicines in areas such as oncology, immunology, and cardiovascular diseases...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E17.0
P/B6.2
P/S2.6
P/FCF10.4
FCF Yield+9.6%
Growth & Outlook
Rev Growth (YoY)+0.6%
EPS Growth (YoY)+3.2%
Revenue 5yr+0.9%
EPS 5yr+2.7%
FCF 5yr-18.0%
Fundamentals
Market Cap$123.8B
Dividend Yield4.3%
Operating Margin+20.5%
ROE+37.7%
Interest Coverage23.1x
Competitive Edge
- The Celgene acquisition (2019) brought Revlimid, now declining, but also Breyanzi (CAR-T) and the TYK2 franchise (deucravacitinib). The pipeline depth from that deal is still generating value years later, with Opdualag and Camzyos in early commercial ramp.
- BMY's oncology franchise (Opdivo, Yervoy, Opdualag, Breyanzi) creates deep prescriber relationships with oncologists, a channel that is notoriously sticky. Switching costs in cancer treatment are high because physicians build protocols around specific agents.
- Cardiovascular franchise diversification through Camzyos (obstructive HCM) and Milvexian (Factor XIa inhibitor in Phase 3) positions BMY in areas with limited competition and high unmet need, reducing dependence on Eliquis before its LOE.
- Manufacturing complexity of biologics like Opdivo and CAR-T therapies creates meaningful barriers to biosimilar entry compared to small molecules. Biosimilar Opdivo competition will be more limited and slower than generic Eliquis competition.
By the Numbers
- Forward P/E of 9.56x vs trailing 17.2x implies consensus expects EPS to nearly double from $3.46 to $6.24, and the PEG of 0.12 suggests the market is drastically underpricing that earnings inflection relative to growth.
- FCF-to-net-income conversion of 1.82x signals earnings quality is actually better than reported GAAP suggests. Heavy non-cash charges (amortization of acquired intangibles) are depressing reported EPS while cash generation runs at $12.8B annually.
- FCF yield of 10.6% with a FCF payout ratio of only 39% leaves substantial room for debt paydown ($4.7B implied by 4.3% debt paydown yield) while maintaining the 4.6% dividend. The company is simultaneously deleveraging and returning cash.
- Capex-to-OCF of just 9.3% and capex-to-depreciation of 0.33x show BMY is a cash machine requiring minimal reinvestment in physical assets, freeing nearly all operating cash flow for shareholders and debt reduction.
- Interest coverage of 32.4x despite $45B in total debt means refinancing risk is negligible even if rates stay elevated. The debt load looks scary in isolation but is easily serviceable against $14B+ in operating cash flow.
Risk Factors
- Consensus revenue estimates show a clear decline trajectory: $46.7B (Y1) to $36.4B (Y5), a 22% cumulative revenue erosion over five years. This is the patent cliff for Eliquis and Opdivo priced into estimates, and the Growth grade of 3/10 confirms it.
- Net debt/EBITDA of 2.46x with goodwill and intangibles comprising 69.5% of total assets means the balance sheet is loaded with acquisition-related assets. Tangible book value per share is negative $11, so equity holders own essentially a stream of future cash flows with no hard asset floor.
- Payout ratio of 71.5% on GAAP earnings looks stretched, though the 39% FCF payout ratio tells a different story. If the patent cliff compresses FCF as expected, that FCF payout ratio could quickly approach uncomfortable levels by Y3-Y4.
- Revenue has been essentially flat for three years (3Y CAGR of 1.4%) while R&D spending runs at 28.4% of revenue, roughly $13.7B annually. The return on that R&D spend needs to materialize in new product launches to offset looming LOE headwinds.
- EPS growth YoY of negative 178% reflects massive one-time charges, but even the 3Y EPS CAGR of 5.5% barely exceeds inflation. Underlying earnings power has not grown meaningfully despite billions in acquisitions.
AT&T Inc. (NYSE: T)
$24.91
Overall Grade6.8 / 10
AT&T Inc. is a diversified telecommunications company operating in wireless, broadband, video, and entertainment services...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E9.7
P/B1.8
P/S1.6
P/FCF14.9
FCF Yield+6.7%
Growth & Outlook
Rev Growth (YoY)+0.7%
EPS Growth (YoY)-2.3%
Revenue 5yr-2.3%
EPS 5yr-0.4%
FCF 5yr+3.1%
Fundamentals
Market Cap$201.9B
Dividend Yield4.5%
Operating Margin+19.8%
ROE+17.9%
Interest Coverage-3.6x
Competitive Edge
- AT&T's fiber buildout creates a structural cost advantage: once passed, fiber homes cost roughly $4-5/month to maintain vs. $15-20 for legacy copper. With 10.4M fiber subs and ARPU of $72.87, each incremental fiber customer displaces a high-cost legacy connection.
- The wireless duopoly with Verizon creates pricing discipline that T-Mobile's growth strategy actually reinforces. T-Mobile targets the value segment, leaving AT&T and Verizon to compete on network quality and bundling, which supports ARPU stability in the $50-57 range.
- FirstNet, the dedicated first-responder network, provides a government-backed subscriber base with near-zero churn and guaranteed spectrum priority. This is a unique asset no competitor can replicate, embedded within the postpaid base but rarely valued separately.
- The WarnerMedia divestiture eliminated content investment risk and refocused capital allocation on network infrastructure with 15-20 year useful lives. Management's discipline in avoiding re-entry into content (unlike Verizon's past missteps) reduces strategic risk.
By the Numbers
- FCF margin of 38.5% dwarfs the net margin of 18.6%, with FCF-to-net-income conversion at 2.07x. This signals earnings quality is actually understated by GAAP, as heavy depreciation ($16.5B implied by capex-to-depreciation near 1.0x) creates a large non-cash drag that cash flow ignores.
- FCF payout ratio of just 16.9% vs. earnings payout ratio of 37.4% means the 4.6% dividend is covered over 5.9x by free cash flow. This gives enormous room for debt reduction, the real priority, while maintaining the dividend.
- Fiber broadband net adds inflected positive, with total broadband net adds surging from -24K in FY2023 to +258K in FY2024 to +729K in FY2025. Fiber now represents 70.8% of total broadband connections vs. 43.3% in FY2021, fundamentally shifting the wireline cost structure.
- At 3.96x P/FCF and 25.2% FCF yield, the market is pricing AT&T as if free cash flow will decline materially. Yet trailing unlevered FCF of $21.7B grew 28% YoY, and capex-to-OCF of 30% suggests the heavy investment cycle is moderating.
- Latin America turned from a $510M operating loss in FY2021 to a $145M profit in FY2025, a $655M swing on just $4.4B revenue. At 3.3% operating margin and accelerating, this segment is transitioning from cash drain to contributor without requiring incremental capital.
Risk Factors
- Postpaid phone churn spiked to 0.90% in FY2025 from 0.76% in FY2024, an 18.4% deterioration. Quarterly data shows sequential worsening (4.8%, 5.7%, 6.5% QoQ increases). This is the single most important leading indicator for wireless ARPU sustainability and it's moving the wrong way.
- Total mobility net adds collapsed 44.5% YoY to 2.31M, with postpaid adds down 22.8% and prepaid losing 536K subscribers. The growth engine is clearly decelerating, and reseller additions (lower-margin MVNO lines) now represent 48% of total net adds vs. essentially zero in FY2021.
- Tangible book value per share is negative $12.02, driven by intangibles comprising 46.8% of total assets and goodwill at 15.1%. This means $155B in total debt is secured against a balance sheet where nearly half the asset base is spectrum licenses and goodwill subject to impairment risk.
- Business Wireline revenue has declined every year for four straight years, accelerating from -5.8% in FY2022 to -9.9% in FY2024 before a modest improvement to -8.4% in FY2025. At $17.2B, this segment still represents 13.7% of total revenue and is a structural drag with no floor in sight.
- Net debt-to-EBITDA of 2.84x with $136.8B net debt means deleveraging to the 2.5x target requires roughly $16B in incremental debt paydown. At current FCF after dividends (~$36B FCF minus ~$8B dividends), this is achievable in roughly 18-24 months, but leaves zero room for investment shortfalls or macro shocks.
Progressive Corporation (NYSE: PGR)
$202.87
Overall Grade6.7 / 10
Progressive Corporation, founded in 1937, is a major U.S. insurance provider specializing in auto, home, and other property and casualty coverages...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E10.1
P/B3.6
P/S1.3
P/FCF6.8
FCF Yield+14.7%
Growth & Outlook
Rev Growth (YoY)+2.0%
EPS Growth (YoY)+2.2%
Revenue 5yr+13.4%
EPS 5yr+33.1%
FCF 5yr+21.9%
Fundamentals
Market Cap$115.8B
Dividend Yield6.9%
Operating Margin+16.6%
ROE+37.1%
Interest Coverage53.3x
Competitive Edge
- Progressive's direct-to-consumer channel and Snapshot telematics create a data feedback loop that competitors like Allstate and GEICO cannot easily replicate. More drivers means better pricing models, which means better loss ratios, which attracts more drivers.
- The bundling strategy through homeowners (via ASI/Homesite) creates switching cost stickiness. Auto-only customers churn at roughly 2x the rate of bundled customers, and Progressive's property segment is now integrated into the personal lines reporting.
- Progressive's agency and direct dual-distribution model gives it access to both price-sensitive shoppers and relationship-driven buyers. GEICO lacks the agency channel, and State Farm lacks the direct digital infrastructure at comparable scale.
- Monthly reporting of financial results (unique among major insurers) creates a transparency advantage that attracts institutional capital and reduces information asymmetry, effectively lowering the company's cost of equity versus peers.
- Regulatory moat in auto insurance is underappreciated. State-by-state rate filing requirements create a 6-18 month lag for competitors to match pricing actions, giving first-movers like Progressive a sustained advantage in rate adequacy cycles.
By the Numbers
- Combined ratio improved from 95.8 in FY2022 to 87.4 in the latest quarter, a 840bps improvement driven primarily by loss ratio compression from 77.3 to 65.9. This is elite underwriting discipline, not just rate adequacy.
- FCF-to-net-income conversion of 1.47x signals high earnings quality. For an insurer, this means reserve releases or favorable loss development are flowing through to cash, not just paper profits.
- Personal Lines net premiums written grew 23.5% in FY2024 and 14.3% in FY2025, compounding on a $38.4B base in FY2021 to $72.6B. Progressive is gaining share at an unprecedented rate while simultaneously improving profitability.
- ROE of 37.1% on a tangible book of $54.51 per share with zero goodwill or intangibles. This is pure operating return, not inflated by acquisition accounting. At 3.7x book, the market is pricing in sustained mid-30s ROE.
- SBC-to-revenue of just 0.14% ($124M on $87.7B revenue) is negligible. Unlike tech companies where SBC masks true costs, Progressive's reported earnings are essentially cash earnings with minimal dilution drag.
Risk Factors
- Forward P/E of 12.45x exceeds trailing P/E of 10.3x, meaning consensus expects EPS to decline from $19.23 to ~$16.38, a 15% drop. The market is pricing in combined ratio normalization, and analysts see FY2025-FY2027 EPS flat to declining.
- Underwriting expense ratio has risen from 17.3 in FY2023 to 21.5 in the latest period, a 24% increase. This offsets loss ratio gains and suggests growth-related spending (advertising, agent commissions) is accelerating faster than premium volume.
- Payout ratio of 70.5% on earnings versus 48.1% on FCF reveals the $13.90 dividend per share is consuming a large share of reported income. If combined ratios revert toward 95, the dividend could become constrained quickly.
- Commercial Lines net premiums written declined 3.1% in FY2025 after years of 8-17% growth. This deceleration, combined with quarterly QoQ volatility of -5.5% and -6.8%, suggests pricing competition or deliberate pullback in a segment that was a key growth driver.
- Revenue growth YoY slowed to just 2% despite 14%+ net premiums written growth, indicating earned premium recognition is lagging written premium growth. This timing gap will eventually close, but near-term reported revenue understates the business trajectory.
Altria Group Inc. (NYSE: MO)
$73.89
Overall Grade6.5 / 10
Altria Group Inc., founded in 1985 and headquartered in Richmond, Virginia, United States, is one of the world’s largest producers and marketers of tobacco products. The company operates mainly in the tobacco industry while also engaging in diversified consumer product investments...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E13.8
P/B-34.3
P/S5.4
P/FCF12.8
FCF Yield+7.8%
Growth & Outlook
Rev Growth (YoY)+1.2%
EPS Growth (YoY)+16.3%
Revenue 5yr-0.7%
EPS 5yr+29.2%
FCF 5yr+1.5%
Fundamentals
Market Cap$110.2B
Dividend Yield5.7%
Operating Margin+54.3%
ROE-243.6%
Interest Coverage10.3x
Competitive Edge
- Marlboro's 42%+ category share creates a distribution lock-in at retail: convenience stores cannot afford to delist the brand, giving Altria guaranteed shelf space and pricing leverage that no competitor can replicate.
- The on! nicotine pouch brand is the only FDA-authorized competitor to Zyn (Swedish Match/PMI) in the fastest-growing tobacco category. First-mover regulatory authorization creates a years-long barrier for new entrants.
- Master Settlement Agreement payments function as a regulatory moat, imposing costs on all domestic cigarette manufacturers proportional to volume, which effectively prevents price-based disruption from new entrants.
- Altria's 10% equity stake in Anheuser-Busch InBev (worth ~$10B) provides a liquid asset buffer and optionality for future capital allocation, partially offsetting the negative tangible book value concern.
By the Numbers
- Smokeable products operating income grew 1.5% YoY to $10.98B despite a 3.4% revenue decline, meaning net revenue per stick is rising fast enough to more than offset 10% annual volume declines. Pricing power is extraordinary.
- ROIC of 24.6% against a 9.2x interest coverage ratio means the spread between return on invested capital and cost of debt is wide, generating significant economic value added even on a shrinking revenue base.
- Forward P/E of 12.0x with a PEG of 0.33 implies the market is pricing in almost no growth, yet consensus EPS estimates rise from $5.60 (Y1) to $6.08 (Y3), a 36% jump from trailing $4.12. The gap between trailing and forward P/E signals a one-time charge depressing current earnings.
- Oral tobacco (on!) shipment volume grew from 48.4M cans in FY2021 to 177.8M in FY2025, a 4-year CAGR of ~38%. Segment operating income surged 26.2% YoY to $1.83B, with margins expanding as the brand scales past investment phase.
- Unlevered FCF of $7.3B against an enterprise value near $117B yields a 6.3% unlevered FCF yield, attractive for a business with minimal capex needs and a 72% gross margin, confirming the cash generation machine is intact despite volume headwinds.
Risk Factors
- Marlboro shipment volume declined 12.2% YoY in FY2025, accelerating from the prior year's 9.0% decline. Total cigarette retail share eroded to 45.2% from 48.7% in FY2021. The volume decline curve is steepening, not stabilizing.
- Negative book value ($-2.08/share) and negative equity produce a meaningless P/B of -31x and ROE of -246%. This isn't just leverage, it reflects cumulative buybacks and dividends exceeding retained earnings, leaving zero equity cushion for creditors.
- Other Operating Income swung to -$2.53B in FY2025 from -$414M in FY2024, a $2.1B deterioration likely tied to NJOY impairment. NJOY device and consumable shipments went to zero, confirming the e-vapor bet has effectively been written off.
- Current ratio of 0.65 and quick ratio of 0.52 signal short-term liquidity is thin. With $25.7B in total debt and only $4.5B in cash, the company depends entirely on continuous cash flow generation to service obligations.
- Discount cigarette shipments surged 41.3% YoY after three consecutive years of 18-30% declines. This reversal suggests consumers are trading down within Altria's portfolio, pressuring revenue per stick and signaling price sensitivity is reaching a threshold.
Comcast Corporation (NASDAQ: CMCSA)
$24.79
Overall Grade6.5 / 10
Comcast Corporation, founded in 1963, is a diversified telecommunications conglomerate operating primarily in the United States. The company delivers a wide range of cable, broadband, and media services across multiple business segments...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E5.7
P/B1.2
P/S0.8
P/FCF5.0
FCF Yield+19.8%
Growth & Outlook
Rev Growth (YoY)+1.3%
EPS Growth (YoY)-5.4%
Revenue 5yr+1.5%
EPS 5yr+10.9%
FCF 5yr+3.4%
Fundamentals
Market Cap$102.7B
Dividend Yield5.3%
Operating Margin+15.3%
ROE+19.8%
Interest Coverage4.3x
Competitive Edge
- Comcast's broadband network is a last-mile infrastructure monopoly/duopoly in most of its footprint. Fixed wireless from T-Mobile and Verizon is taking share but cannot match cable's speed and latency at scale, preserving pricing power for now.
- Peacock reaching 44M paid subscribers (up 22% YoY) gives Comcast a direct-to-consumer asset that monetizes its NBCUniversal content library without relying solely on declining linear TV distribution fees.
- Theme Parks revenue surged 14.1% YoY to $9.8B with Epic Universe opening in Orlando in 2025. This is a high-margin, physically scarce asset that competitors cannot easily replicate and provides counter-cyclical diversification from connectivity.
- The Xfinity Mobile MVNO leverages Verizon's network with minimal capex, creating a bundling tool that reduces broadband churn. At 9.3M lines growing nearly 19% annually, it is approaching scale where it contributes meaningful standalone economics.
- Owning both content (NBCUniversal, DreamWorks) and distribution (Xfinity, Sky) creates vertical integration that allows Comcast to negotiate from strength with third-party programmers and retain exclusive content windows for Peacock.
By the Numbers
- FCF yield of 21.3% with FCF-to-net-income conversion of 1.11x signals high earnings quality. The company generates more cash than reported profits, which is rare for a media conglomerate carrying $99B in debt and heavy content spend.
- Total shareholder yield of 9.3% (4.4% dividend + 7.0% buyback + 2.2% debt paydown) at a 22% FCF payout ratio means capital returns are running at less than half of cash generation capacity. Significant room to accelerate returns or invest.
- Domestic wireless lines grew 18.9% YoY to 9.3M, adding 1.48M lines in FY2025, the fastest net add pace since FY2022. This is the only customer metric accelerating and is becoming a meaningful offset to broadband subscriber erosion.
- Connectivity & Platforms EBITDA margin expanded from 37% in FY2021 to 40% in FY2025 despite flat revenue, showing disciplined cost extraction. Average monthly revenue per customer relationship rose to $131.77, up 1.8% over two years while subs declined.
- Capex-to-depreciation of 0.73x means the company is spending well below replacement cost, harvesting its installed cable plant. This is intentional cash flow maximization from a mature asset base, directly funding the 21% FCF yield.
Risk Factors
- Domestic broadband residential net losses accelerated to -654K in FY2025 from -375K in FY2024, a 74% worsening. Total connectivity customer relationships lost 967K, nearly double the prior year. The subscriber base is in structural decline.
- Tangible book value per share is -$12.52, driven by intangibles comprising 52.6% of total assets and goodwill at 22.6%. The $1.06 P/B ratio masks that equity is entirely dependent on the assumed value of acquired media and cable assets.
- Revenue is essentially flat: 0.6% 3Y CAGR and -0.02% YoY. Yet trailing EPS of $5.39 drops to estimated $3.69 in Y1, a 31% decline. The gap between trailing and forward P/E (5.5x vs 8.1x) reflects an expected earnings reset, likely from the planned spin-off.
- Current ratio of 0.88 and quick ratio of 0.70 indicate short-term liabilities exceed liquid assets. With $99B in total debt and LT debt-to-capital at 99.4%, the balance sheet is heavily leveraged even by cable industry standards.
- Content & Experiences EBITDA fell 48.5% QoQ in the most recent quarter to $1B, while the segment's revenue grew 8.5% QoQ. This margin collapse suggests either a content write-down or heavy investment cycle that is destroying near-term segment profitability.
Verizon Communications Inc (NYSE: VZ)
$47.51
Overall Grade6.2 / 10
Verizon Communications Inc. is a global leader in delivering communications, technology, information, and entertainment products and services...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E12.2
P/B2.0
P/S1.5
P/FCF10.3
FCF Yield+9.7%
Growth & Outlook
Rev Growth (YoY)+0.7%
EPS Growth (YoY)+1.2%
Revenue 5yr+0.8%
EPS 5yr-5.1%
FCF 5yr-2.1%
Fundamentals
Market Cap$209.6B
Dividend Yield6.0%
Operating Margin+21.2%
ROE+16.9%
Interest Coverage4.2x
Competitive Edge
- Verizon's 5G C-band spectrum holdings create a durable capacity advantage over T-Mobile in dense urban markets. Spectrum is a finite, government-allocated resource with no substitute, making it the closest thing to a permanent moat in wireless.
- Fixed wireless access is cannibalizing cable broadband (Comcast, Charter) without requiring last-mile fiber buildout. Verizon is reusing existing tower infrastructure, turning a wireless asset into a broadband competitor at fraction of traditional deployment cost.
- The 6.7% dividend yield at current prices creates a natural floor for institutional and income-oriented holders. In a declining rate environment, this yield becomes increasingly attractive relative to fixed income alternatives, compressing downside risk.
- Fios fiber footprint in the Northeast corridor serves the densest, highest-ARPU markets in the U.S. Unlike cable competitors facing fiber overbuild risk, Verizon already owns the fiber, giving it structural cost advantages in its served territories.
- Wireless industry consolidation to three national carriers (Verizon, T-Mobile, AT&T) creates rational pricing discipline. DISH/EchoStar remains a weak fourth player, reducing the risk of a price war that would compress industry margins.
By the Numbers
- PEG of 0.49 against a forward P/E of 10.3x signals the market is underpricing Verizon's estimated EPS growth from $4.06 trailing to $4.91 in Y1 and $5.21 in Y2, a 21% and 28% cumulative increase that the valuation barely reflects.
- FCF yield of 9.6% with FCF-to-net-income conversion of 1.14x indicates earnings quality is strong. Cash generation exceeds reported profits, meaning the income statement actually understates economic earnings power.
- Consumer broadband connections grew 8.4% YoY to 10.86M, the fastest-growing KPI in the portfolio. This fixed wireless access ramp is layering a second revenue stream onto existing wireless infrastructure with minimal incremental capex.
- Consumer ARPA grew from $122.30 in FY2021 to $138.25 in FY2024, a 13% cumulative increase, while postpaid connections grew only 3.9% over the same period. Monetization per account is doing the heavy lifting, not subscriber volume.
- Capex-to-depreciation of 0.93x means Verizon is spending less on capex than it depreciates, suggesting the C-band buildout cycle is peaking. As capex normalizes lower, FCF should expand even on flat revenue.
Risk Factors
- Net debt of $162.6B at 2.93x EBITDA with interest coverage of only 7.1x leaves thin margin for error. At current OCF-to-debt of 23.4%, it would take over 4 years of entire operating cash flow to retire total debt, and that ignores dividends and capex.
- EPS has declined at a -7.1% 3-year CAGR and -1.1% over 5 years despite stable revenue, meaning margin compression and rising interest expense are eating into profitability. The Growth grade of 3.6/10 confirms this structural weakness.
- Consumer wireless postpaid net adds fell 56.8% YoY to 581K in FY2025 while Q3 showed a sharp QoQ decline before a Q4 surge. The volatility suggests promotional dependency rather than organic demand, and the annual trend is clearly decelerating from the 2.04M peak in FY2023.
- Business segment revenue has declined for four consecutive years, from $31.07B in FY2022 to $29.07B in FY2025, a cumulative 6.4% erosion. Business operating income fell 26% from FY2021 to FY2024 before a partial bounce. This segment is structurally shrinking.
- Tangible book value per share is negative $20.30, driven by intangibles comprising 47% of total assets. The $181.6B debt load sits on top of a balance sheet where nearly half the assets are spectrum licenses and goodwill, assets that cannot be easily liquidated.
Amgen Inc. (NASDAQ: AMGN)
$330.33
Overall Grade6.2 / 10
Amgen Inc. is a pioneering biotechnology company operating in the health care sector, founded in 1980 and headquartered in Thousand Oaks, California...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E24.5
P/B20.7
P/S5.1
P/FCF22.1
FCF Yield+4.5%
Growth & Outlook
Rev Growth (YoY)+1.3%
EPS Growth (YoY)+1.0%
Revenue 5yr+7.5%
EPS 5yr+6.9%
FCF 5yr+5.5%
Fundamentals
Market Cap$189.9B
Dividend Yield3.1%
Operating Margin+28.4%
ROE+87.4%
Interest Coverage3.9x
Competitive Edge
- Amgen's bone franchise (Prolia at $4.4B plus EVENITY at $2.1B) creates a $6.5B osteoporosis duopoly with no credible biosimilar threat to EVENITY for years. The sequential treatment paradigm, EVENITY then Prolia, locks in patients across both products.
- The Horizon acquisition gave Amgen TEPEZZA, the only FDA-approved treatment for thyroid eye disease, a true orphan-like monopoly. With $1.9B in revenue and limited competition on the horizon, this is a high-margin, defensible cash flow stream.
- Amgen's biologics manufacturing expertise, including its proprietary BiTE platform (BLINCYTO) and next-gen bispecifics, creates a structural barrier. Few competitors can replicate the scale of Amgen's global biologics supply chain at comparable cost.
- TEZSPIRE's partnership with AstraZeneca in severe asthma positions Amgen in a massive respiratory market with differentiated mechanism (anti-TSLP). The 52% YoY growth to $1.5B suggests the drug is winning share against Dupixent in biologic-naive patients.
- R&D spend at 19.8% of revenue ($7.3B annually) funds a deep pipeline including MariTide (obesity, partnered with Lilly-competitive mechanism), rocatinlimab (atopic dermatitis), and bemarituzumab (gastric cancer), each addressing multi-billion dollar markets.
By the Numbers
- PEG of 0.28 against a forward P/E of 16.1x signals the market is dramatically underpricing Amgen's earnings growth trajectory. Consensus expects EPS to jump from $14.23 trailing to $22.40 in Y1, a 57% step-up that compresses the multiple quickly.
- FCF-to-net-income conversion of 1.05x confirms high earnings quality. Unlike many large pharma peers that rely on working capital tricks, Amgen's reported profits are fully backed by cash generation, with $7.5B+ in annual unlevered FCF.
- Repatha revenue compounded at 35%+ for two consecutive years (FY2024 +35.9%, FY2025 +35.7%), reaching $3B. Combined with EVENITY at $2.1B (+34.4%) and TEZSPIRE at $1.5B (+52.1%), these three growth franchises now represent ~$6.6B, or 18% of total revenue.
- BLINCYTO's revenue trajectory from $472M in FY2021 to $1.56B in FY2025 (3.3x in four years) with consistent quarterly sequential growth reflects genuine label expansion in ALL, not just pricing. This is the kind of durable oncology franchise that commands premium multiples.
- SBC-to-revenue at just 1.3% is exceptionally lean for a biotech of this scale. For context, that's roughly $490M against $36.7B revenue, meaning shareholder dilution from compensation is minimal and reported margins closely approximate cash-based economics.
Risk Factors
- ENBREL's accelerating decline, from -10.3% in FY2024 to -32.9% in FY2025, erased $1.1B of revenue in a single year. This franchise is now at $2.2B and falling fast as biosimilar competition intensifies. The decline rate suggests a cliff, not a glide path.
- Net debt of $45.5B at 2.87x EBITDA with interest coverage of only 5.2x is tight for a pharma company facing patent cliffs. With $54.6B total debt and a debt-to-equity ratio of 5.8x, refinancing risk is real if rates stay elevated. The debt grade of 3.5/10 confirms this.
- Cash conversion cycle of 217 days is alarmingly high, driven by 200 days of inventory. Inventory turnover at 1.8x suggests either manufacturing inefficiency, channel build for new launches, or potential obsolescence risk on legacy products. This deserves scrutiny.
- FCF growth has badly lagged revenue growth: 5-year FCF CAGR of 0.76% versus 7.6% revenue CAGR. The FCF conversion trend score of -1 confirms deterioration. Rising capex (5.1% of revenue) and working capital absorption are eating into cash generation improvements.
- Tangible book value per share is negative $59.59, reflecting $44.6B in intangibles and goodwill (45% of assets). The Horizon Therapeutics acquisition loaded the balance sheet with goodwill at 20.6% of assets, creating meaningful impairment risk if TEPEZZA or KRYSTEXXA underperform.
Procter & Gamble Company (The) (NYSE: PG)
$141.47
Overall Grade6.0 / 10
Procter & Gamble Company, founded in 1837, is a multinational consumer goods company that manufactures and markets a wide range of personal care, household, and health products. It operates in global markets with a strong presence in both developed and emerging economies...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E21.1
P/B6.2
P/S3.9
P/FCF22.4
FCF Yield+4.5%
Growth & Outlook
Rev Growth (YoY)+1.7%
EPS Growth (YoY)+1.3%
Revenue 5yr+2.1%
EPS 5yr+3.9%
FCF 5yr-4.8%
Fundamentals
Market Cap$336.3B
Dividend Yield3.0%
Operating Margin+23.2%
ROE+30.9%
Interest Coverage23.7x
Competitive Edge
- P&G's category leadership in laundry (Tide), diapers (Pampers), razors (Gillette), and oral care (Oral-B) creates shelf-space lock-in with retailers. Losing a P&G planogram slot costs a retailer more traffic than it costs P&G in volume.
- The company's supply chain scale, spanning 100+ countries, creates a cost advantage that private label and DTC brands cannot replicate. This is why Fabric & Home Care margins keep expanding even as pricing growth slows.
- P&G's portfolio pruning over the past decade, from 170+ brands to roughly 65, concentrated resources on categories with structural repurchase cycles. Consumables like detergent and toothpaste have near-zero demand elasticity in developed markets.
- Distribution partnerships with Walmart, Costco, and Amazon give P&G first-mover data on consumer purchasing shifts. These relationships are decades old and create co-investment dynamics that new entrants cannot easily access.
By the Numbers
- ROIC of 18% with interest coverage at 27x and net debt/EBITDA of only 0.64x shows the balance sheet is working hard without being stretched. This is a company earning well above its cost of capital with minimal leverage risk.
- Negative cash conversion cycle of -38 days means P&G collects from customers and turns inventory before paying suppliers. DPO of 129 days versus DIO of 64 days gives them a permanent working capital float that funds operations.
- Health Care segment EBT grew 7.1% YoY on only 1.7% revenue growth, implying significant margin expansion. Health Care EBT margin reached 26.2%, up from 24.9% the prior year, making it the fastest-improving profit pool.
- Fabric & Home Care EBT margin expanded from 24.9% in FY2024 to 25.2% in FY2025, and this segment now contributes $7.5B in pre-tax income on $29.6B revenue. It is 35% of sales but 37% of segment profits, and margins are still expanding.
- FCF-to-net-income conversion of 0.90x and OCF-to-net-income of 1.15x confirm high earnings quality. SBC is only 0.58% of revenue, trivial dilution compared to the 1.4% buyback yield that actively shrinks the share count.
Risk Factors
- Organic sales growth decelerated from 7% in FY2022/FY2023 to 4% in FY2024 to just 2% in FY2025, with the most recent quarter showing 0% organic growth and -1% organic volume. The pricing engine that drove post-COVID growth is exhausted.
- Beauty segment EBT fell 9.2% YoY to $3.45B while revenue declined 1.7%. Beauty EBT margin compressed from 25% to 23.1% over two years, the worst margin trajectory of any segment. Capex there jumped 17%, suggesting defensive spending.
- FCF growth has been negative on a 3-year (-0.7% CAGR) and 5-year (-4.2% CAGR) basis despite positive earnings growth. Capex-to-depreciation of 1.42x signals reinvestment is outpacing wear, compressing free cash flow even as net income rises.
- PEG ratio of 6.93 is extreme. With EPS growing at roughly 5% annually and the stock at 22x earnings, you are paying a steep premium per unit of growth. Forward P/E of 21.8x on $6.96 estimated EPS implies almost no multiple compression benefit.
- Tangible book value per share is negative at -$4.25, driven by goodwill and intangibles comprising 50% of total assets. The 6.5x P/B multiple rests entirely on brand value and earnings power, leaving zero asset-based downside support.
International Business Machines Corporation (NYSE: IBM)
$221.50
Overall Grade5.8 / 10
International Business Machines Corporation (IBM) is a global technology company that delivers a broad range of hardware, software, and consulting services for enterprise customers. Founded in 1911 and headquartered in the United States, IBM has evolved from a traditional computing equipment provider into a leader in cloud and cognitive solutions...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E21.4
P/B6.9
P/S3.3
P/FCF17.6
FCF Yield+5.7%
Growth & Outlook
Rev Growth (YoY)+2.0%
EPS Growth (YoY)+1.4%
Revenue 5yr+9.4%
EPS 5yr+12.2%
FCF 5yr+7.9%
Fundamentals
Market Cap$227.8B
Dividend Yield3.1%
Operating Margin+18.2%
ROE+32.6%
Interest Coverage6.4x
Competitive Edge
- The Kyndryl spin-off removed a low-margin, declining managed infrastructure business, leaving IBM with a structurally higher-margin portfolio. This is a one-time portfolio reset that permanently improves the company's growth and margin profile.
- IBM's mainframe installed base creates deep switching costs. Migrating off z-series requires rewriting decades of COBOL applications, which costs more than upgrading. This captive base generates recurring Transaction Processing and software revenue with near-zero churn.
- The Red Hat acquisition gives IBM control of the leading enterprise Linux and Kubernetes platform, positioning it as the neutral hybrid cloud layer between AWS, Azure, and GCP. Enterprises avoiding single-cloud lock-in are IBM's core buyers.
- WatsonX and the broader AI strategy are monetizing through consulting engagements and software attach rates rather than competing directly with hyperscalers on foundation models. This is a smarter go-to-market than trying to out-invest Microsoft or Google on raw AI infrastructure.
- IBM's federal and regulated industry relationships (banking, healthcare, defense) create a distribution moat. These customers prioritize security clearances, compliance certifications, and long vendor relationships over cutting-edge technology, favoring incumbents.
By the Numbers
- Software segment income grew 14.2% YoY on 10.6% revenue growth in FY2025, with gross margins at 83.5%. This operating leverage means each incremental software dollar drops more to the bottom line, and software now represents 44% of total revenue, up from 41% in FY2022.
- FCF-to-net-income conversion of 1.03x confirms earnings quality is real. Unlike many IT services peers where restructuring charges and acquisition amortization create gaps between GAAP earnings and cash, IBM's cash generation closely tracks reported profits.
- Infrastructure segment income surged 41.1% YoY in FY2025 on just 12.1% revenue growth, with gross margins expanding 280bps to 58.6%. This signals a new mainframe cycle (likely z16 refresh) driving high-margin hardware and attached software revenue.
- Consulting gross margins improved for the fourth consecutive year, reaching 28.1% in FY2025 from 25.5% in FY2022. A 260bps expansion in a people-intensive business suggests pricing discipline and successful automation of lower-value delivery work.
- EPS growth of 73.7% YoY and 83.8% 3Y CAGR dramatically outpaces revenue growth of 7.6% YoY, reflecting the mix shift toward software, margin expansion across all segments, and disciplined cost management post-Kyndryl spin-off.
Risk Factors
- Consulting signings fell 13.2% YoY to $21.8B in FY2025, and the book-to-bill ratio dropped from 1.21 to 1.03. A ratio barely above 1.0 means the backlog is essentially flat, signaling potential revenue pressure in Consulting over the next 12-18 months.
- The payout ratio at 89% of earnings and 88.4% of FCF leaves almost no margin of safety for the $10.11/share dividend. Any earnings miss or working capital disruption would force IBM to fund the dividend with debt, compounding an already leveraged balance sheet.
- Tangible book value per share is negative $49, driven by goodwill and intangibles representing 52% of total assets. This acquisition-heavy balance sheet carries real impairment risk if the acquired software assets (HashiCorp, Apptio, etc.) underperform expectations.
- Net debt of $50.2B at 2.3x EBITDA is manageable but not comfortable, especially with a current ratio below 1.0 at 0.96. IBM is running with thin liquidity and relying on continuous cash generation to service obligations. Refinancing $64.6B of total debt in a higher-rate environment compresses margins.
- Estimated EBIT for Y1-Y5 ($8.7B to $10.1B) is actually below trailing EBIT of $12.3B, suggesting analysts expect corporate costs or restructuring to absorb segment-level profit gains. The gap between segment income totals (~$16.4B) and reported EBIT ($12.3B) reveals roughly $4B in unallocated costs.
PepsiCo Inc. (NASDAQ: PEP)
$149.99
Overall Grade5.8 / 10
PepsiCo Inc., founded in 1898 and restructured in 1965, is a global multinational operating in the food, snack, and beverage industry. It serves consumers in over 200 countries with a wide-ranging portfolio of products...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E23.6
P/B9.6
P/S2.2
P/FCF23.2
FCF Yield+4.3%
Growth & Outlook
Rev Growth (YoY)+1.6%
EPS Growth (YoY)+6.2%
Revenue 5yr+3.7%
EPS 5yr+3.0%
FCF 5yr+1.0%
Fundamentals
Market Cap$205.3B
Dividend Yield4.0%
Operating Margin+12.7%
ROE+41.8%
Interest Coverage10.5x
Competitive Edge
- PepsiCo's dual food-and-beverage model creates unique distribution synergies. Frito-Lay's direct-store-delivery network covers over 300,000 U.S. retail locations, giving snack brands shelf-space control that Mondelez, Kellanova, and pure-play competitors cannot replicate at comparable cost.
- The FY2025 segment reorganization (merging Frito-Lay and Quaker into PFNA, creating IB Franchise) signals management is optimizing for margin extraction and accountability. Consolidating the struggling Quaker business under Frito-Lay's stronger management team could accelerate the recall recovery.
- PepsiCo's franchise-based international beverage model (IB Franchise segment grew operating profit 21% YoY) is asset-light and high-margin. This structure mirrors Coca-Cola's bottler refranchising playbook, reducing capital intensity while capturing concentrate economics.
- Category positioning in salty snacks is structurally advantaged. Frito-Lay holds ~60% U.S. market share in salty snacks, a category with high impulse-purchase frequency, low private-label penetration, and minimal GLP-1 drug exposure compared to sugary beverages or confections.
- Emerging market food platforms in Latin America and Asia Pacific provide long-duration growth runways. LatAm Foods generates 19% operating margins on $10.5B revenue, and the category benefits from rising snacking occasions as developing-market consumers shift toward packaged convenience foods.
By the Numbers
- PEG ratio of 0.41 is striking given forward P/E of 18.1x, implying consensus expects ~44% EPS growth from trailing $6.00 to $8.63 in Y1. That gap between trailing and forward earnings suggests FY2025 had significant one-time charges depressing the $6 trailing EPS figure.
- ROIC of 13.5% comfortably exceeds PepsiCo's weighted average cost of capital (likely 7-8%), confirming the business still creates real economic value despite 2.4x debt/equity. The 42.8% ROE is amplified by leverage but the underlying asset productivity at 9% ROA is solid for consumer staples.
- Negative cash conversion cycle of -124 days is a massive working capital advantage. PepsiCo collects from customers and turns inventory far faster than it pays suppliers (DPO of 213 days), effectively using vendor financing to fund operations and reduce capital needs.
- SBC/revenue at just 0.3% is negligible, meaning reported margins closely approximate true cash economics. Unlike tech peers, virtually no hidden dilution cost is embedded in the P&L, and buybacks (0.43% yield) are genuinely returning capital rather than offsetting option grants.
- FCF-to-net-income conversion of 0.92x is healthy, and OCF-to-net-income of 1.46x shows strong cash generation above reported earnings. Capex/depreciation at 1.06x means the company is roughly maintaining its asset base without overinvesting, keeping free cash flow clean.
Risk Factors
- FCF payout ratio at 99.8% leaves essentially zero margin of safety for the dividend. With $5.58 FCF per share and $5.58 dividend per share, any modest decline in free cash flow forces either dividend cuts or incremental borrowing to maintain the payout.
- Total organic volume declined 2% company-wide in FY2025 while net pricing grew 4%, meaning 100% of organic revenue growth came from price increases. This pricing-over-volume dynamic has persisted for three years and raises demand elasticity risk as consumer pushback builds.
- PBNA segment operating profit collapsed 52.7% YoY to $1.09B despite revenue growing 1.5%. Operating margin cratered from ~8.3% to ~3.9%, suggesting either a major restructuring charge, competitive pricing pressure, or cost inflation that management couldn't offset in the beverage business.
- Tangible book value per share is negative at -$9.89, with intangibles/goodwill comprising 31.6% of total assets. The 10.3x P/B multiple rests entirely on brand value and earnings power. Any impairment to the $17.6B goodwill balance would directly hit equity.
- Current ratio of 0.85 and quick ratio of 0.64 indicate short-term liabilities exceed liquid assets. While common for consumer staples with strong cash flows, combined with net debt/EBITDA of 2.5x and $49B total debt, refinancing risk is non-trivial if credit markets tighten.
I’ll be honest, this is one of the more interesting lists I’ve put together. Not because every name here is a slam dunk, but because the variety forces you to think about what you actually want from a U.S. dividend holding. Some of these companies are growing fast enough that the current yield is almost beside the point. Others are mature businesses where the payout itself is doing most of the work for you. Both approaches can make you money, but confusing one for the other is how people end up disappointed.
The thing I keep coming back to with U.S. dividend stocks is durability. Canadian investors already have yield at home. What you’re crossing the border for is access to business models and sectors that give your income stream a different foundation. If you’re just chasing a higher number on a screen, you’re missing the point entirely.
Be selective. Own the ones you understand, and know exactly why each one earned a spot in your portfolio.
